Bibliometric Analysis of Research on Mental Health in the Workplace in Canada 1991-2002

This paper uses the Medline biomedical papers database to measure scientific production on mental health in the workplace (MHWP) during the 1991-2002 period at the world, Canadian, provincial, urban, institutional and researcher levels. The level of scientific output has doubled at the world level and tripled at the Canadian level during the last 12 years. At the provincial level, Ontario, Quebec, British Columbia and Alberta are leading in absolute number of papers. Ontario largely dominates both in terms of output and on a per capita basis. At the level of cities, Toronto and Montreal are the largest producers of papers on MHWP. The most important institutions in terms of papers on MHWP are McMaster University, Université de Montréal, the University of Toronto, the University of British Columbia and the University of Western Ontario. The universities with the largest number of active researchers in MHWP are McMaster University, Université Laval and York University

Research impact of paywalled versus open access papers

This note presents data from the 1science OAIndx on the average of relative citations (ARC) for 3.3 million papers published from 2007 to 2009 and indexed in the Web of Science (WoS). These data show a decidedly large citation advantage for open access (OA) papers, despite them suffering from a lag in availability compared to paywalled papers. There is an abundant literature on the citation advantage of OA papers, starting with a succinct communication by Lawrence (2001). Several studies have been listed by SPARC, the majority of which support the idea that when papers are openly available, they are more cited than papers for which availability is restricted to those who pay for access (http://sparceurope.org/oaca/). As noted by Diana Hicks on the ScienceMetrics.org blog (http://sciencemetrics.org/oaca-open-accesscitation- advantage/), skeptics argue that the advantage of OA is partly due to citations having a chance to arrive sooner. Another purported artefact would be a selection bias according to which authors pick their best (hence most citeable) papers to make OA. This paper examines the first aspect and concludes that the purported head start of OA papers is actually contrary to observed data. The limitation of the existing literature on the subject, whether supporting or refuting the OA citation advantage, is often the small number of articles analyzed, the limited size and diversity of the citing sources, and the short citation window considered. The present note examines 3,350,910 papers published between 2007 and 2009 and indexed in the WoS, with a citation window starting in 2007 and continuing up to the latest date possible (in practice, mid-2016). More than 12,000 journals indexed in the WoS were used to compute the citation

Comparative performance of adult social care research, 1996-2011: a bibliometric assessment

Decision-makers in adult social care are increasingly interested in using evidence from research to support or shape their decisions. The scope and nature of the current landscape of adult social care research (ASCR) needs to be better understood. This paper provides a bibliometric assessment of ASCR outputs from 1996 to 2011. ASCR papers were retrieved using three strategies: from key journals; using keywords and noun phrases; and from additional papers preferentially citing or being cited by other ASCR papers. Overall 195,829 ASCR papers were identified in the bibliographic database Scopus, of which 16% involved at least one author from the UK. The UK output increased 2.45-fold between 1996 and 2011. Among selected countries, those with greater research intensity in ASCR generally had higher citation impact, such as the US, UK, Canada and the Netherlands. The top-5 UK institutions in terms of volume of papers in the UK accounted for 26% of total output. We conclude by noting the limitations to bibliometric analysis of ASCR and examine how such analysis can support the strategic development of the field

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination.

The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to improve immune responses against Omicron subvariants, bivalent mRNA vaccines have recently been approved in several countries. In this study, we measure the capacity of plasma from vaccinated individuals, before and after a fourth dose of mono- or bivalent mRNA vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before and after the fourth dose, we observe a significantly better recognition and neutralization of the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been recently infected better recognize and neutralize the BQ.1.1 Spike, independently of the mRNA vaccine used, than donors who have never been infected or have an older infection. Our study supports that hybrid immunity, generated by vaccination and a recent infection, induces higher humoral responses than vaccination alone, independently of the mRNA vaccine used

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

The dynamics of pharmaceutical patenting in India: Evidence from USPTO data

This article analyses the impact of the implementation of the 'Agreement on Trade-Related Aspects of Intellectual Property Rights' (TRIPS) on various segments of the Indian pharmaceutical industry. In particular, it focuses on the conditions under which a strong patent system can create benefits for a developing country's pharmaceutical industry. The theoretical analysis suggests that the greater the technological capabilities of the Indian pharmaceutical industry the greater are its chances to benefit from the introduction of stronger intellectual property rights (IPRs). The evidence presented paints a generally positive picture of the state of the Indian pharmaceutical industry, with the existence of strong and growing technological competencies that can be used as a platform for further expansion. These conclusions are dependent on India's worldwide success in the industry and cannot be automatically applied to other developing countries, especially if their pharmaceutical industry is not strong at the moment of the transition to a stronger IPR regime

Research impact of paywalled versus open access papers

This note presents data from the 1science OAIndx on the average of relative citations (ARC) for 3.3 million papers published from 2007 to 2009 and indexed in the Web of Science (WoS). These data show a decidedly large citation advantage for open access (OA) papers, despite them suffering from a lag in availability compared to paywalled papers. There is an abundant literature on the citation advantage of OA papers, starting with a succinct communication by Lawrence (2001). Several studies have been listed by SPARC, the majority of which support the idea that when papers are openly available, they are more cited than papers for which availability is restricted to those who pay for access (http://sparceurope.org/oaca/). As noted by Diana Hicks on the ScienceMetrics.org blog (http://sciencemetrics.org/oaca-open-accesscitation- advantage/), skeptics argue that the advantage of OA is partly due to citations having a chance to arrive sooner. Another purported artefact would be a selection bias according to which authors pick their best (hence most citeable) papers to make OA. This paper examines the first aspect and concludes that the purported head start of OA papers is actually contrary to observed data. The limitation of the existing literature on the subject, whether supporting or refuting the OA citation advantage, is often the small number of articles analyzed, the limited size and diversity of the citing sources, and the short citation window considered. The present note examines 3,350,910 papers published between 2007 and 2009 and indexed in the WoS, with a citation window starting in 2007 and continuing up to the latest date possible (in practice, mid-2016). More than 12,000 journals indexed in the WoS were used to compute the citation

Genomics in Norway - Overview of Research in Genomics in Norway

<p>This report presents an overview of genome research in Norway using data from the Internet and from the Medline database. </p><p>Part I presents an overview of genomic research programs in Norway. In Norway, genome research is financed by a single government agency that provides financial support via a national research programme on functional genomics (FUGE). This program supports the research activities organized through ten technology platforms. Although Norway's global output in genomics papers is fairly low overall – the country lags behinds the other Scandinavian countries - Norwegian genomics has grown steadily during the last decade. Part I also presents data from the Internet on Norwegian universities, government and health sector institutions as well as companies that are active in the field. </p><p>Drawing from the Medline database, Part II examines the distribution of papers in genomics by sector, institution, city, and researcher. The distribution of research in genomics in Norway is concentrated in three locations: </p><p>Oslo: its output of papers is unmatched: it hosts the leading university and four of the nine leading hospitals. Almost all of the country's leading researchers come from the leading hospital, located in Oslo. </p><p>Bergen: it ranks second in scientific output, hosts the second most productive university and second most productive hospital. </p><p>Tromsø: the city ranks third in terms of scientific output and hosts the third most productive university. </p><p>The private sector represents a very low proportion of Norway's scientific output (1% of scientific papers). </p&gt

Le saumon atlantique de la rivière Matane : croissance marine, abondance des retours en rivière et indice de l’oscillation nord-atlantique

L’abondance du saumon atlantique (Salmo salar) dans le nord de l’Atlantique a diminué considérablement au cours des dernières décennies. Jusqu’à maintenant, peu de stocks ont montré des signes de rétablissement malgré des efforts importants pour renverser cette situation. Les niveaux décroissants d’abondance des saumons adultes de retour en rivière pourraient être associés à une augmentation de la mortalité naturelle en mer découlant d’une réduction de la croissance. La présente étude a pour but de vérifier si 2 indices de croissance scalaire en phase marine (la distance intercirculi maximale atteinte lors de la première saison estivale en mer et la somme des distances intercirculi de la zone de croissance marine des écailles) et l’abondance des retours de saumon dans la rivière Matane (Québec, Canada) appuient cette hypothèse. Bien que ces indices présentent des différences interannuelles significatives, ils affichent une tendance à la hausse de 1964 à 1979 et une tendance à la baisse de 1995 à 2012. Ces tendances sont semblables à celles des retours de saumons adultes en rivière et à celles de l’indice de l’oscillation nord-atlantique (IONA). Ces similitudes concordent avec l’hypothèse d’une relation inverse entre la croissance marine et la mortalité et, conséquemment, les variations d’abondance qui en résultent.The abundance of Atlantic salmon (Salmo salar) in the North Atlantic has declined significantly in recent decades. Despite substantial efforts to reverse this trend, few stocks have shown signs of recovery. The decreasing number of adult salmon returning to rivers may be due to an increase in natural marine mortality linked to a reduction in growth. The present study aimed to verify whether this hypothesis was supported by two marine phase scalar growth indices (the maximum intercirculi distance attained during the first summer at sea and the total intercirculi distance of the marine growth zone) and the abundance of salmon returning to the Matane River (Québec, Canada). Although the two indices show significant interannual differences, they show an upward trend from 1964 to 1979 and a downward trend from 1995 to 2012. These trends are similar to those of river returns by adult salmon and to the North Atlantic Oscillation Index (NAOI). These similarities support the hypothesis of an inverse relationship between marine growth and mortality, which would subsequently result in variations in abundance